The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.c

Pleural thickening - Fibrothorax

Publications

Helsen V, Decoutere L, Spriet I, Fagard K, Boonen S, Tournoy J

Ergotamine-induced pleural and pericardial effusion successfully treated with colchicine.

Acta clinica Belgica. 2013;68(2):113-5

Allen MB, Tosh G, Walters G, Muers MF

Pleural and pericardial fibrosis after ergotamine therapy.

Respiratory medicine. 1994;88(1):67-9

Seaton A

Pleural and pericardial fibrosis after ergotamine therapy.

Respiratory medicine. 1994;88(6):480

Taal BG, Spierings EL, Hilvering C

Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine.

Thorax. 1983;38(5):396-8

Ibsen KK, Lindeneg O

[Ergotamine treatment and pleuritis].

Ugeskrift for laeger. 1979;141(13):860